SCHEDULE OF CHANGES IN INVESTMENT (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
Jan. 31, 2026 |
Jan. 31, 2025 |
Jan. 31, 2026 |
Jan. 31, 2025 |
Jul. 31, 2025 |
|
| Restructuring Cost and Reserve [Line Items] | |||||
| Funding (including the value of the BC Therapeutics Options) | $ 165,000 | $ 150,000 | |||
| Share of losses: | $ (61,993) | $ (42,584) | (106,823) | (114,099) | |
| BC Therapeutics Inc [Member] | |||||
| Restructuring Cost and Reserve [Line Items] | |||||
| Beginning balance | 524,278 | $ 418,490 | $ 418,490 | ||
| Funding (including the value of the BC Therapeutics Options) | 165,000 | 330,000 | |||
| Share of losses: | (106,823) | (224,212) | |||
| Ending balance | $ 582,455 | $ 582,455 | $ 524,278 | ||
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of investment in equity method investee and investment in and advance to affiliate. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow associated with the purchase of all investments (debt, security, other) during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|